List of Excipients in Branded Drug ZOSYN

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Wyeth Pharmaceuticals Inc a subsidiary of Pfizer Inc	ZOSYN	piperacillin sodium and tazobactam sodium	0206-2409	DEXTROSE MONOHYDRATE
Wyeth Pharmaceuticals Inc a subsidiary of Pfizer Inc	ZOSYN	piperacillin sodium and tazobactam sodium	0206-2409	EDETATE DISODIUM
Wyeth Pharmaceuticals Inc a subsidiary of Pfizer Inc	ZOSYN	piperacillin sodium and tazobactam sodium	0206-2409	HYDROCHLORIC ACID

Zosyn Excipient Strategy and Commercial Opportunities: Piperacillin/Tazobactam Formulation, Generic Entry, and Market Analysis

Last updated: September 24, 2026

Zosyn is the branded injectable combination of piperacillin sodium and tazobactam sodium. Its commercial opportunity is no longer based on conventional small-molecule patent exclusivity. The principal value drivers are sterile manufacturing capability, intravenous compatibility, ready-to-use packaging, supply reliability, hospital contracting, and differentiated stability profiles.

The formulation is relatively simple compared with many drug products. That simplicity reduces excipient-related patent opportunities but increases the importance of process control, container closure systems, reconstitution performance, sodium load, osmolality, and product stability.

What is Zosyn and how is it formulated?

Zosyn contains piperacillin sodium, an extended-spectrum penicillin antibiotic, and tazobactam sodium, a beta-lactamase inhibitor. The product is administered intravenously for serious bacterial infections, including intra-abdominal, skin and skin-structure, and hospital-acquired or community-acquired pneumonia indications under the approved labeling.[1]

Zosyn dosage forms and strengths

Product presentation	Piperacillin/tazobactam strength	Primary formulation characteristics
Single-dose vial	2.25 g	Sterile powder for reconstitution
Single-dose vial	3.375 g	Sterile powder for reconstitution
Single-dose vial	4.5 g	Sterile powder for reconstitution
GALAXY container	2.25 g, 3.375 g, or 4.5 g	Premixed intravenous solution in dextrose
Generic vial products	Equivalent strengths	Sterile powder, generally reconstituted before dilution

The powder presentations contain the active ingredients as sodium salts. The premixed GALAXY presentations use dextrose injection as the infusion vehicle. Depending on the presentation, the formulation may have no conventional inactive excipient in the powder and may rely on the diluent, container, and manufacturing process to achieve the required product performance.[1]

What excipients are used in Zosyn?

The most important excipient distinction is between Zosyn powder for reconstitution and Zosyn premixed infusion products.

Powder-for-injection strategy

The powder formulation is based primarily on piperacillin sodium and tazobactam sodium. The absence of a substantial excipient system provides several advantages:

• Lower risk of excipient-mediated incompatibility.
• Smaller label and regulatory burden.
• Reduced risk of hypersensitivity or intolerance associated with additional formulation ingredients.
• Simpler lyophilization or sterile powder manufacturing.
• More direct comparison with generic injectable products.

The formulation challenge is chemical and physical stability. Piperacillin and tazobactam must remain stable during storage, reconstitution, dilution, and infusion. The product must also meet sterility, particulate, potency, pH, and degradation limits under the applicable injectable-drug standards.[1][2]

Premixed infusion strategy

The GALAXY presentations are supplied in dextrose injection. Dextrose is not a pharmacologically active excipient, but it affects commercial positioning and clinical workflow. The premixed container reduces pharmacy compounding steps and supports faster administration in hospitals.

The relevant formulation variables include:

• Dextrose concentration.
• Final pH.
• Osmolality.
• Stability during frozen storage and thawing.
• Stability after thawing at controlled room temperature or refrigeration.
• Compatibility with infusion devices.
• Container extractables and leachables.
• Adsorption or permeation through the polymer container.
• Visual appearance and particulate control.

The dextrose vehicle also limits the use case for patients or protocols where a saline-based diluent is preferred. A saline premix, if technically and regulatorily feasible, could create a differentiated product, but it would require stability and compatibility data rather than a simple vehicle substitution.

Which excipient attributes matter most for commercial competition?

The commercial formulation opportunity is concentrated in performance attributes rather than in adding novel excipients.

Sodium exposure

Both active ingredients are supplied as sodium salts. Total sodium exposure can matter in critically ill patients, patients with renal impairment, and patients receiving multiple sodium-containing intravenous products. A lower-sodium formulation could have clinical and commercial value, but changing the counterion or active pharmaceutical ingredient form would create a major chemistry, manufacturing, and controls burden.

A manufacturer seeking a lower-sodium profile would need to establish:

1. Identity and purity of the active ingredients.
2. Equivalent antimicrobial potency.
3. Comparable impurity profiles.
4. Acceptable reconstitution behavior.
5. Compatible pH and osmolality.
6. Stability throughout the proposed shelf life.
7. Clinical or regulatory justification for the changed composition.

A lower-sodium claim would therefore be more difficult than a conventional generic formulation change.

Diluent selection

Common diluents for piperacillin/tazobactam administration include 0.9% sodium chloride injection and 5% dextrose injection, subject to product-specific labeling and compatibility conditions.[1] A commercial product that offers validated stability in additional diluents could reduce pharmacy waste and improve hospital flexibility.

The opportunity is strongest where the product provides:

• Longer in-use stability after reconstitution.
• Clearer storage instructions.
• Ready-to-administer packaging.
• Reduced need for aseptic compounding.
• Compatibility with automated infusion systems.
• A formulation suitable for extended or continuous infusion protocols.

Container and delivery system

For an injectable antibiotic, the container can be as commercially important as the excipient system. Potential platforms include:

• Conventional glass vials.
• Polymer vials.
• Flexible premix bags.
• Ready-to-use bottles.
• Dual-chamber containers.
• Pharmacy bulk packages.
• Elastomeric infusion devices.

A dual-chamber system could separate the dry drug from the diluent until administration. This could improve stability and simplify preparation, but it would require device development, combination-product analysis, human-factors evaluation, and new extractables and leachables work.

What patents protect Zosyn and its formulation?

Zosyn's principal U.S. patent-based exclusivity has expired. The branded product originated with Wyeth and is now marketed under Pfizer following Pfizer's acquisition of Wyeth in 2009.[3]

The core composition is an established combination of piperacillin and tazobactam. Patent protection that once covered the drug combination, manufacturing technology, or approved uses is generally no longer a practical barrier to U.S. generic entry. The commercial focus has shifted from blocking patents to regulatory approval, manufacturing economics, and supply execution.

Orange Book status

Zosyn is associated with FDA New Drug Application 050684. Current Orange Book analysis should distinguish between:

• The reference listed drug designation.
• Any remaining listed patents.
• Pediatric exclusivity.
• Product-specific exclusivity.
• Patents listed for a particular dosage form or use.

The relevant commercial conclusion is that Zosyn does not have the profile of an actively patent-protected innovative product with a near-term loss-of-exclusivity event. Generic piperacillin/tazobactam products have been marketed in the United States for years, confirming that the core product is accessible through the ANDA pathway.[4]

When did Zosyn lose exclusivity?

Zosyn lost meaningful U.S. market exclusivity before the current generic market matured. The product is now a mature hospital injectable with multiple approved generic or alternative suppliers.

Exclusivity category	Current commercial significance
New chemical entity exclusivity	Expired
Core composition patents	Expired or no longer a practical barrier to routine generic entry
Formulation exclusivity	No known active barrier comparable to a protected modern specialty product
Pediatric exclusivity	Not a current barrier to ordinary generic competition
Reference product status	Remains relevant for ANDA equivalence
Generic access	Established

The timing of individual generic launches depends on FDA approval dates, manufacturing capacity, drug shortages, and procurement contracts. A single patent expiration date does not determine current competition because the market already includes generic suppliers.

Which companies compete with Zosyn?

The competitive field includes Pfizer's branded Zosyn and manufacturers of generic piperacillin/tazobactam products. Supplier participation can vary by strength, presentation, facility status, and temporary shortage conditions.

Competitive categories

Segment	Competitive proposition
Branded Zosyn	Established clinical recognition and hospital formulary familiarity
Generic sterile powder	Lowest-cost substitution and broad hospital use
Premixed infusion	Reduced pharmacy preparation and labor
Ready-to-administer systems	Workflow and medication-safety benefits
Contract-manufactured supply	Volume pricing and institutional purchasing
Alternative beta-lactam regimens	Clinical substitution based on indication, resistance, renal function, and formulary policy

Generic suppliers commonly compete on unit price, fill rate, shortage performance, and ability to supply all major strengths. In hospital procurement, a supplier with a dependable sterile injectable network can win share even without a novel excipient profile.

What formulation patents could create new commercial value?

New patents would be more likely to cover a delivery system, stability profile, packaging configuration, or manufacturing process than the basic piperacillin/tazobactam composition.

Potentially protectable formulation concepts

1. Room-temperature stable premix
   A product that avoids frozen distribution could reduce pharmacy handling and inventory costs.

2. Extended post-reconstitution stability
   A validated product with longer storage after reconstitution could support centralized pharmacy preparation and continuous infusion.

3. Dual-chamber delivery system
   The dry product and diluent remain separated until use, reducing degradation during shelf storage.

4. Low-sodium formulation
   A reduced-sodium product could target patients with fluid or sodium restrictions, although the chemistry burden would be substantial.

5. Alternative buffer system
   A buffer could improve pH control or stability, but the buffer itself may introduce compatibility and tolerability issues.

6. Ready-to-use elastomeric device
   This could support outpatient parenteral antimicrobial therapy and home infusion.

7. Container-specific stability protection
   Polymer selection, oxygen control, moisture protection, or light protection could support a patentable package-product combination.

A formulation patent would need claims that are difficult to design around and tied to measurable product performance. Broad claims covering piperacillin/tazobactam with a conventional diluent would face substantial validity and obviousness risk because the combination and common infusion vehicles are established.

What manufacturing and intellectual-property barriers exist?

The main barriers are operational rather than foundational composition patents.

Sterile manufacturing

Piperacillin/tazobactam products require validated aseptic processing, sterile filtration or sterile powder handling, environmental controls, and robust container-closure integrity testing. Sterile injectable facilities are expensive to build and difficult to qualify.

Stability and degradation

The active ingredients may be sensitive to pH, temperature, moisture, and time after reconstitution. A manufacturer must control:

• Water content.
• Residual solvents and process impurities.
• Degradation products.
• Reconstitution time.
• Solution clarity.
• Particulate matter.
• Compatibility with diluents and administration sets.

Supply chain resilience

Piperacillin/tazobactam is a hospital-critical antibiotic. Shortages can rapidly increase demand for alternative suppliers. Manufacturers with multiple API sources, redundant fill-finish capacity, and validated backup packaging have a commercial advantage.

Regulatory burden

A generic applicant must demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy the applicable injectable-product requirements. For parenteral products, the regulatory emphasis is on qualitative and quantitative composition, strength, sterility, impurities, stability, and manufacturing comparability.[5]

What FDA regulatory status applies to Zosyn and its generics?

Zosyn is an FDA-approved injectable antibiotic. Generic versions are generally approved through the ANDA pathway when they meet the requirements for sameness and therapeutic equivalence to the reference product.[1][4]

The FDA regulatory opportunities are strongest in these areas:

• New premixed presentations.
• Improved container systems.
• New strengths or presentation formats.
• Extended stability claims.
• Products designed for outpatient infusion.
• Products that reduce compounding steps.
• Packaging that improves medication safety.

A reformulated product that changes the active ingredient form, diluent, concentration, or administration method may require a more complex submission than a standard ANDA. A 505(b)(2) pathway could become relevant for a materially differentiated product, but the regulatory route would depend on the proposed changes and supporting data.

What licensing deals affect Zosyn?

Pfizer's ownership reflects the Wyeth acquisition rather than a current formulation-specific licensing transaction. No major active licensing structure is necessary to commercialize a standard generic piperacillin/tazobactam product, although companies may use contract manufacturing, API supply agreements, distribution agreements, or hospital group-purchasing contracts.

The most commercially relevant deal structures are likely to involve:

• API supply and dual sourcing.
• Contract sterile fill-finish.
• Premix-bag manufacturing.
• Regional distribution.
• Hospital purchasing organizations.
• Outpatient parenteral antimicrobial therapy networks.

How large is the revenue opportunity?

Zosyn revenue is no longer separately reported by Pfizer in a way that supports a current, product-level revenue estimate. The branded product competes in a largely generic hospital market, and revenue is sensitive to contract losses, shortages, government purchasing, and generic substitution.

Commercial value remains available in four areas:

Opportunity	Revenue logic
Generic powder vial	Volume-driven, low-margin institutional sales
Premixed infusion	Higher value per unit through workflow savings
Ready-to-use outpatient product	Expansion into home infusion and ambulatory care
Supply-resilient product	Premium procurement position during shortages

The strongest business case is usually a differentiated sterile injectable platform rather than another undifferentiated vial. A premix or ready-to-administer system can command better economics if it reduces pharmacy labor, preparation errors, inventory complexity, or waste.

What generic launch scenarios exist?

Low-cost standard generic

This approach uses a conventional sterile powder vial and competes on price. It has the lowest development complexity but also the greatest exposure to price erosion.

Premium premix

A premixed product in dextrose or another validated vehicle targets hospital pharmacy efficiency. The product must justify its price through labor savings, reduced preparation, and dependable stability.

Outpatient infusion product

An elastomeric or ready-to-administer presentation could target home infusion providers. The commercial opportunity depends on stability, portability, device reliability, and reimbursement.

Shortage-resilient supplier

A manufacturer with multiple production sites and strong inventory control can capture share during supply interruptions. This is a procurement advantage rather than a patent advantage.

How strong is the Zosyn patent estate?

The Zosyn patent estate is weak as a current barrier to generic competition. The core active ingredients and combination are mature, generic products are established, and the commercial moat is based on manufacturing and distribution rather than enforceable exclusivity.

A new entrant should evaluate patent risk around its own formulation or device claims, not assume that the legacy Zosyn estate provides meaningful protection. The most defensible new claims would likely require a specific technical result, such as improved stability under defined storage conditions, a novel container system, or a distinct administration format.

Key Takeaways

• Zosyn is piperacillin sodium plus tazobactam sodium for intravenous administration.
• The powder formulation has a limited conventional excipient burden.
• Premixed Zosyn uses a dextrose-based infusion vehicle and creates greater formulation and packaging differentiation.
• Core Zosyn exclusivity has expired, and generic competition is established.
• Current barriers are sterile manufacturing, stability, supply reliability, and hospital contracting.
• The strongest commercial opportunities are premixed, ready-to-use, extended-stability, low-waste, and outpatient-infusion products.
• New patent value would most likely arise from formulation performance, packaging, delivery systems, or manufacturing processes.
• A standard generic vial is a volume business with substantial price pressure.
• A differentiated ready-to-administer product may support stronger margins and broader clinical workflow adoption.

FAQs

Is Zosyn still patent protected?

Zosyn's core patent-based exclusivity has expired. Current market access is dominated by generic competition and manufacturing execution.

Does Zosyn contain preservatives?

Zosyn injectable products are not generally positioned as preserved multidose formulations. Product-specific labeling should be used to confirm the composition of each presentation.

Can piperacillin/tazobactam be sold in a saline premix?

A saline premix may be technically possible, but it requires product-specific stability, compatibility, container, and regulatory support. It is not equivalent to simply changing the diluent in an approved presentation.

Is there a commercial opportunity in a lower-sodium Zosyn formulation?

Potentially, but the opportunity carries significant chemistry, regulatory, and clinical-development risk because the approved ingredients are sodium salts and the sodium content is tied to the active pharmaceutical ingredient forms.

What is the best patent strategy for a new piperacillin/tazobactam product?

The strongest strategy would focus on technically specific claims covering a stable ready-to-use formulation, a dual-chamber or elastomeric delivery system, extended post-reconstitution stability, or a container configuration that produces a measurable performance benefit.

References

1. Pfizer Inc. (2023). Zosyn (piperacillin sodium and tazobactam sodium) for injection prescribing information. U.S. Food and Drug Administration.

2. United States Pharmacopeia. (2024). General chapter <1>, injections and implanted drug products. United States Pharmacopeial Convention.

3. Pfizer Inc. (2009). Pfizer completes acquisition of Wyeth. Pfizer investor and corporate communications materials.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2023). ANDAs for certain highly purified synthetic peptides and parenteral drug products: Regulatory guidance and product-specific recommendations. U.S. Department of Health and Human Services.